Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares

On Feb. 2, Hussman Strategic Advisors, Inc. disclosed in a U.S. Securities and Exchange Commission filing that it sold out its entire position in TG Therapeutics (NASDAQ:TGTX).

• Exited 126,000 shares in TG Therapeutics.

• The stake previously represented 1.0% of fund AUM as of the prior quarter

TG Therapeutics is a commercial-stage biotechnology company specializing in innovative therapies for B-cell malignancies and autoimmune diseases. It leverages a diversified pipeline of monoclonal antibodies and small-molecule inhibitors, positioning itself to address unmet needs in hematologic oncology and immunology.

With a focus on both development and commercialization, TG Therapeutics aims to expand its market presence through strategic partnerships and a robust clinical program. Its approach combines scientific innovation with targeted market execution to create a competitive edge in the biotechnology sector.

• Develops and commercializes therapies for B-cell malignancies and autoimmune diseases, with a portfolio including Ublituximab, Umbralisib, Cosibelimab, and several preclinical candidates.

• Operates a commercial-stage biopharmaceutical business model, generating revenue primarily through the sale and licensing of proprietary drug candidates.

• Targets healthcare providers and patients in oncology and immunology markets, focusing on hematologic cancers and autoimmune disorders.

Prior to selling its entire stake in the fourth quarter, TG Therapeutics was one of Hussman Strategic Advisors’ major holdings. The 126,000 it held as of Sept. 30 had a value of $4.6 million. The fifth largest holding, the position accounted for 1% of Hussman’s assets under management (AUM).

TG Therapeutics shares have underperformed compared to major indexes, losing 11.8% over the last year through Jan. 30. That compares to the Nasdaq Composite’ and S&P 500 index’s total returns of 20% and 15.8%, respectively. The indexes returns include dividends.

A stock losing money doesn’t feel good, obviously. But it’s particularly painful when the stock market has done particularly well. That’s because you could’ve invested passively in an index fund.

Turning to the financial results, the company stated preliminary fourth-quarter revenue for its main product came in at $182 million. Total third-quarter revenue grew by 92.8% to $161.7 million.

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $495,739!*

• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $49,363!*

• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $450,256!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.

See the 3 stocks »

*Stock Advisor returns as of February 2, 2026

Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Etsy and Qualcomm. The Motley Fool recommends TG Therapeutics, Ubiquiti, and United Natural Foods. The Motley Fool has a disclosure policy.

Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares was originally published by The Motley Fool